210 related articles for article (PubMed ID: 25130488)
21. 14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma.
Lee CH; Ou WB; Mariño-Enriquez A; Zhu M; Mayeda M; Wang Y; Guo X; Brunner AL; Amant F; French CA; West RB; McAlpine JN; Gilks CB; Yaffe MB; Prentice LM; McPherson A; Jones SJ; Marra MA; Shah SP; van de Rijn M; Huntsman DG; Dal Cin P; Debiec-Rychter M; Nucci MR; Fletcher JA
Proc Natl Acad Sci U S A; 2012 Jan; 109(3):929-34. PubMed ID: 22223660
[TBL] [Abstract][Full Text] [Related]
22. p53 immunohistochemical analysis of fusion-positive uterine sarcomas.
Mohammad N; Stewart CJR; Chiang S; Turashvili G; Dickson BC; Ng TL; Köbel M; McCluggage WG; Croce S; Lee CH
Histopathology; 2021 May; 78(6):805-813. PubMed ID: 33118176
[TBL] [Abstract][Full Text] [Related]
23. Prognostic value of alternative lengthening of telomeres-associated biomarkers in uterine sarcoma and uterine carcinosarcoma.
Lee YK; Park NH; Lee H
Int J Gynecol Cancer; 2012 Mar; 22(3):434-41. PubMed ID: 22266933
[TBL] [Abstract][Full Text] [Related]
24. Analysis of clinicopathologic prognostic factors for 157 uterine sarcomas and evaluation of a grading score validated for soft tissue sarcoma.
Pautier P; Genestie C; Rey A; Morice P; Roche B; Lhommé C; Haie-Meder C; Duvillard P
Cancer; 2000 Mar; 88(6):1425-31. PubMed ID: 10717626
[TBL] [Abstract][Full Text] [Related]
25. Uterine leiomyosarcomas: tumor size, mitotic index, and biomarkers Ki67, and Bcl-2 identify two groups with different prognosis.
D'Angelo E; Espinosa I; Ali R; Gilks CB; Rijn Mv; Lee CH; Prat J
Gynecol Oncol; 2011 May; 121(2):328-33. PubMed ID: 21316747
[TBL] [Abstract][Full Text] [Related]
26. Prognostic factors and expression of p53 and mdm-2 in uterine sarcomas.
Kim SH; Kim JW; Kim YT; Kim JH; Yoon BS; Ryu HS
Int J Gynaecol Obstet; 2006 Dec; 95(3):272-7. PubMed ID: 16930603
[TBL] [Abstract][Full Text] [Related]
27. Uterine sarcoma-current management and experience from a regional cancer centre in North India.
Biswas A; Patel F; Kumar P; Srinivasan R; Bera A; Sharma SC; Rajwanshi A
Arch Gynecol Obstet; 2013 Oct; 288(4):873-82. PubMed ID: 23580012
[TBL] [Abstract][Full Text] [Related]
28. Progesterone Receptor Expression Is an Independent Prognosticator in FIGO Stage I Uterine Leiomyosarcoma.
Davidson B; Kjæreng ML; Førsund M; Danielsen HE; Kristensen GB; Abeler VM
Am J Clin Pathol; 2016 Apr; 145(4):449-58. PubMed ID: 27149024
[TBL] [Abstract][Full Text] [Related]
29. Wilms tumor gene 1 (WT1) is a prognostic marker in high-grade uterine sarcoma.
Coosemans A; Van Calster B; Verbist G; Moerman P; Vergote I; Van Gool SW; Amant F
Int J Gynecol Cancer; 2011 Feb; 21(2):302-8. PubMed ID: 21734473
[TBL] [Abstract][Full Text] [Related]
30. Prognostic factors in uterine sarcoma.
Gadducci A
Best Pract Res Clin Obstet Gynaecol; 2011 Dec; 25(6):783-95. PubMed ID: 21764643
[TBL] [Abstract][Full Text] [Related]
31. Frequent expression of KIT in endometrial stromal sarcoma with YWHAE genetic rearrangement.
Lee CH; Hoang LN; Yip S; Reyes C; Marino-Enriquez A; Eilers G; Tao D; Chiang S; Fletcher JA; Soslow RA; Nucci MR; Oliva E
Mod Pathol; 2014 May; 27(5):751-7. PubMed ID: 24186140
[TBL] [Abstract][Full Text] [Related]
32. "Low-grade leiomyosarcoma" and late-recurring smooth muscle tumors of the uterus: a heterogenous collection of frequently misdiagnosed tumors associated with an overall favorable prognosis relative to conventional uterine leiomyosarcomas.
Veras E; Zivanovic O; Jacks L; Chiappetta D; Hensley M; Soslow R
Am J Surg Pathol; 2011 Nov; 35(11):1626-37. PubMed ID: 21921786
[TBL] [Abstract][Full Text] [Related]
33. Uterine sarcomas: a review.
D'Angelo E; Prat J
Gynecol Oncol; 2010 Jan; 116(1):131-9. PubMed ID: 19853898
[TBL] [Abstract][Full Text] [Related]
34. Insulin-like growth factor type 1 receptor expression correlates to good prognosis in highly malignant soft tissue sarcoma.
Ahlén J; Wejde J; Brosjö O; von Rosen A; Weng WH; Girnita L; Larsson O; Larsson C
Clin Cancer Res; 2005 Jan; 11(1):206-16. PubMed ID: 15671548
[TBL] [Abstract][Full Text] [Related]
35. High-grade endometrial stromal sarcoma versus undifferentiated uterine sarcoma: a Turkish uterine sarcoma group study-001.
Ayhan A; Tunc M; Boran N; Khatib G; Gokcu M; Simsek T; Ozen OI; Toptas T; Yalcin I; Meydanli MM
Arch Gynecol Obstet; 2021 Aug; 304(2):475-483. PubMed ID: 33392719
[TBL] [Abstract][Full Text] [Related]
36. Identification of a novel, recurrent MBTD1-CXorf67 fusion in low-grade endometrial stromal sarcoma.
Dewaele B; Przybyl J; Quattrone A; Finalet Ferreiro J; Vanspauwen V; Geerdens E; Gianfelici V; Kalender Z; Wozniak A; Moerman P; Sciot R; Croce S; Amant F; Vandenberghe P; Cools J; Debiec-Rychter M
Int J Cancer; 2014 Mar; 134(5):1112-22. PubMed ID: 23959973
[TBL] [Abstract][Full Text] [Related]
37. Gynecologic Cancer InterGroup (GCIG) consensus review for high-grade undifferentiated sarcomas of the uterus.
Pautier P; Nam EJ; Provencher DM; Hamilton AL; Mangili G; Siddiqui NA; Westermann AM; Reed NS; Harter P; Ray-Coquard I
Int J Gynecol Cancer; 2014 Nov; 24(9 Suppl 3):S73-7. PubMed ID: 25341584
[TBL] [Abstract][Full Text] [Related]
38. [Uterine sarcomas: clinical and histopathological aspects. Report on 15 cases].
Leung F; Terzibachian JJ; Aouar Z; Govyadovskiy A; Lassabe C
Gynecol Obstet Fertil; 2008 Jun; 36(6):628-35. PubMed ID: 18538624
[TBL] [Abstract][Full Text] [Related]
39. Advances in the diagnosis and treatment of uterine sarcomas.
Dizon DS; Birrer MJ
Discov Med; 2014 Jun; 17(96):339-45. PubMed ID: 24979254
[TBL] [Abstract][Full Text] [Related]
40. Description of a Novel ERBB4 -rearranged Uterine Sarcoma.
Lim SH; Mansor SB; Kathirvel R; Kuick CH; Lim-Tan SK; McCluggage WG
Int J Gynecol Pathol; 2022 Sep; 41(5):508-513. PubMed ID: 34570017
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
